The potential role of α2 agonists for noncardiac surgery

摘要

Unfortunately, the alpha2 agonist data are reported only as differences between group scores, rather than the percentage of patients in each treatment group who experienced a clinically important change being reported. Despite this limitation, it is possible, and considering the differences between group pain scores and the opioid sparing-effects, perhaps even probable, that alpha2 agonists resulted in an appreciable relative increase in the number of patients experiencing a clinically important reduction in their pain scores.